ISIN | LU1540962054 |
---|---|
Valor Number | 35004489 |
Bloomberg Global ID | |
Fund Name | HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund P USD Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 446.37 USD | 25.06.2025 |
---|---|---|
Previous Price * | 448.78 USD | 24.06.2025 |
52 Week High * | 522.40 USD | 08.11.2024 |
52 Week Low * | 392.02 USD | 08.04.2025 |
NAV * | 446.37 USD | 25.06.2025 |
Issue Price * | 446.37 USD | 25.06.2025 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 18,164,745 | |
Unit/Share Assets *** | 14,555,735 | |
Trading Information SIX |
YTD Performance | -3.34% |
31.12.2024 - 25.06.2025
31.12.2024 25.06.2025 |
---|---|---|
YTD Performance (in CHF) | -14.27% |
31.12.2024 - 25.06.2025
31.12.2024 25.06.2025 |
1 month | +2.52% |
26.05.2025 - 25.06.2025
26.05.2025 25.06.2025 |
3 months | -4.27% |
25.03.2025 - 25.06.2025
25.03.2025 25.06.2025 |
6 months | -4.04% |
27.12.2024 - 25.06.2025
27.12.2024 25.06.2025 |
1 year | -7.06% |
25.06.2024 - 25.06.2025
25.06.2024 25.06.2025 |
2 years | +8.92% |
26.06.2023 - 25.06.2025
26.06.2023 25.06.2025 |
3 years | +20.07% |
29.06.2022 - 25.06.2025
29.06.2022 25.06.2025 |
5 years | -3.66% |
30.06.2020 - 25.06.2025
30.06.2020 25.06.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
argenx SE | 7.92% | |
---|---|---|
Gilead Sciences Inc | 6.07% | |
Vertex Pharmaceuticals Inc | 5.26% | |
Alnylam Pharmaceuticals Inc | 5.12% | |
Amgen Inc | 5.07% | |
Ascendis Pharma AS ADR | 4.22% | |
Axsome Therapeutics Inc | 3.79% | |
Regeneron Pharmaceuticals Inc | 3.44% | |
Merus NV | 3.42% | |
Arcutis Biotherapeutics Inc Ordinary Shares | 3.39% | |
Last data update | 31.03.2025 |
TER | 0.0133% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 2.39% |
SRRI ***
|
|
SRRI date *** | 31.05.2025 |